Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway.

Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Cornud F, Haider MA, Macura KJ, Tempany CM, Verma S, Weinreb JC.

Radiology. 2019 Aug;292(2):464-474. doi: 10.1148/radiol.2019182946. Epub 2019 Jun 11.

PMID:
31184561
2.

Prostate Imaging-Reporting and Data System Steering Committee: PI-RADS v2 Status Update and Future Directions.

Padhani AR, Weinreb J, Rosenkrantz AB, Villeirs G, Turkbey B, Barentsz J.

Eur Urol. 2019 Mar;75(3):385-396. doi: 10.1016/j.eururo.2018.05.035. Epub 2018 Jun 13.

3.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169
4.
5.

Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.

Tewes S, Hueper K, Hartung D, Imkamp F, Herrmann TR, Weidemann J, Renckly S, Kuczyk MA, Wacker F, Peters I.

World J Urol. 2015 Nov;33(11):1707-14. doi: 10.1007/s00345-015-1525-4. Epub 2015 Mar 14.

PMID:
25774003
6.

Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.

Sheridan AD, Nath SK, Syed JS, Aneja S, Sprenkle PC, Weinreb JC, Spektor M.

AJR Am J Roentgenol. 2018 Feb;210(2):347-357. doi: 10.2214/AJR.17.18516. Epub 2017 Nov 7.

PMID:
29112469
7.

Prebiopsy Multiparametric MRI With Cancer-Negative Findings in Men With Suspected Prostate Cancer: Evaluation Using Prostate Imaging Reporting and Data System Version 2.

Kim JG, Kim CK, Kim JH.

AJR Am J Roentgenol. 2018 Jul;211(1):121-126. doi: 10.2214/AJR.17.18926. Epub 2018 Apr 30.

PMID:
29708783
8.

Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.

Venderink W, van Luijtelaar A, Bomers JG, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, Sedelaar JP, Fütterer JJ.

Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110-0. doi: 10.1016/j.eururo.2017.02.021. [Epub ahead of print]

PMID:
28258784
9.

Multicentre evaluation of magnetic resonance imaging supported transperineal prostate biopsy in biopsy-naïve men with suspicion of prostate cancer.

Hansen NL, Barrett T, Kesch C, Pepdjonovic L, Bonekamp D, O'Sullivan R, Distler F, Warren A, Samel C, Hadaschik B, Grummet J, Kastner C.

BJU Int. 2018 Jul;122(1):40-49. doi: 10.1111/bju.14049. Epub 2017 Nov 15.

10.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

11.

Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.

Mertan FV, Greer MD, Shih JH, George AK, Kongnyuy M, Muthigi A, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

J Urol. 2016 Sep;196(3):690-6. doi: 10.1016/j.juro.2016.04.057. Epub 2016 Apr 18.

PMID:
27101772
12.

Performance of Combined Magnetic Resonance Imaging/Ultrasound Fusion-guided and Systematic Biopsy of the Prostate in Biopsy-naïve Patients and Patients with Prior Biopsies.

Preisser F, Theissen L, Wenzel M, Humke C, Bodelle B, Köllermann J, Kluth L, Banek S, Becker A, Roos F, Chun FK, Mandel P.

Eur Urol Focus. 2019 Jul 8. pii: S2405-4569(19)30170-1. doi: 10.1016/j.euf.2019.06.015. [Epub ahead of print]

PMID:
31296485
13.

The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.

Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, Asbach P, Haas M, Hinz S, Neymeyer J, Miller K, Günzel K, Kempkensteffen C.

World J Urol. 2016 Apr;34(4):525-32. doi: 10.1007/s00345-015-1671-8. Epub 2015 Aug 21.

PMID:
26293117
14.

Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.

Washino S, Okochi T, Saito K, Konishi T, Hirai M, Kobayashi Y, Miyagawa T.

BJU Int. 2017 Feb;119(2):225-233. doi: 10.1111/bju.13465. Epub 2016 Apr 1.

15.

Primary magnetic resonance imaging/ultrasonography fusion-guided biopsy of the prostate.

Maxeiner A, Kittner B, Blobel C, Wiemer L, Hofbauer SL, Fischer T, Asbach P, Haas M, Penzkofer T, Fuller F, Miller K, Cash H.

BJU Int. 2018 Aug;122(2):211-218. doi: 10.1111/bju.14212. Epub 2018 Apr 17.

16.

Diagnostic accuracy of magnetic resonance imaging (MRI) prostate imaging reporting and data system (PI-RADS) scoring in a transperineal prostate biopsy setting.

Grey AD, Chana MS, Popert R, Wolfe K, Liyanage SH, Acher PL.

BJU Int. 2015 May;115(5):728-35. doi: 10.1111/bju.12862. Epub 2014 Oct 22.

17.

Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment.

Bjurlin MA, Meng X, Le Nobin J, Wysock JS, Lepor H, Rosenkrantz AB, Taneja SS.

J Urol. 2014 Sep;192(3):648-58. doi: 10.1016/j.juro.2014.03.117. Epub 2014 Apr 21. Review.

18.

Prospective nonrandomized study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy to magnetic resonance imaging with subsequent MRI-guided biopsy in biopsy-naïve patients.

Castellucci R, Linares Quevedo AI, Sánchez Gómez FJ, Díez Rodríguez J, Cogorno L, Cogollos Acuña I, Salmerón Béliz I, Muñoz Fernández de Legaría M, Martínez Piñeiro L.

Minerva Urol Nefrol. 2017 Dec;69(6):589-595. doi: 10.23736/S0393-2249.17.02845-4.

19.

Prostate cancer detection rates of magnetic resonance imaging-guided prostate biopsy related to Prostate Imaging Reporting and Data System score.

Osses DF, van Asten JJ, Kieft GJ, Tijsterman JD.

World J Urol. 2017 Feb;35(2):207-212. doi: 10.1007/s00345-016-1874-7. Epub 2016 Jun 10.

PMID:
27287889
20.

Multiparametric MRI and targeted prostate biopsy: Improvements in cancer detection, localization, and risk assessment.

Bjurlin MA, Mendhiratta N, Wysock JS, Taneja SS.

Cent European J Urol. 2016;69(1):9-18. doi: 10.5173/ceju.2016.734. Epub 2016 Jan 25. Review.

Supplemental Content

Support Center